- Home
- GF vs NVRO Comparison
GF vs NVRO Comparison
Compare GF & NVRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- NVRO
- Stock Information
- Founded
- GF 1990
- NVRO 2006
- Country
- GF Germany
- NVRO United States
- Employees
- GF N/A
- NVRO N/A
- Industry
- GF Investment Managers
- NVRO Medical/Dental Instruments
- Sector
- GF Finance
- NVRO Health Care
- Exchange
- GF Nasdaq
- NVRO Nasdaq
- Market Cap
- GF 138.1M
- NVRO 134.5M
- IPO Year
- GF N/A
- NVRO 2014
- Fundamental
- Price
- GF $7.93
- NVRO $3.79
- Analyst Decision
- GF
- NVRO Hold
- Analyst Count
- GF 0
- NVRO 14
- Target Price
- GF N/A
- NVRO $7.97
- AVG Volume (30 Days)
- GF 28.1K
- NVRO 446.9K
- Earning Date
- GF 01-01-0001
- NVRO 11-11-2024
- Dividend Yield
- GF 0.82%
- NVRO N/A
- EPS Growth
- GF N/A
- NVRO N/A
- EPS
- GF N/A
- NVRO N/A
- Revenue
- GF N/A
- NVRO $419,146,000.00
- Revenue This Year
- GF N/A
- NVRO N/A
- Revenue Next Year
- GF N/A
- NVRO $0.65
- P/E Ratio
- GF N/A
- NVRO N/A
- Revenue Growth
- GF N/A
- NVRO N/A
- 52 Week Low
- GF $7.38
- NVRO $3.52
- 52 Week High
- GF $9.41
- NVRO $22.53
- Technical
- Relative Strength Index (RSI)
- GF 32.28
- NVRO 37.79
- Support Level
- GF $8.09
- NVRO $3.92
- Resistance Level
- GF $8.44
- NVRO $4.29
- Average True Range (ATR)
- GF 0.10
- NVRO 0.28
- MACD
- GF -0.03
- NVRO -0.03
- Stochastic Oscillator
- GF 7.80
- NVRO 26.67
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a United States-based non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About NVRO Nevro Corp.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.